How changes in Medicare policy affect the use of calcimimetics in dialysis patients
Incentive Payments and Practice Patterns in Dialysis: The Case of Calcimimetics
This study looks at how a new Medicare policy that made it easier for dialysis patients to get calcimimetics—medications that help with a condition called secondary hyperparathyroidism—has affected their health and treatment outcomes.
Quick facts
| Grant type | Fellowship grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | Stanford University NIH-funded |
| Lab location | 1 site (Stanford, United States) |
| Project ID | NIH-11024339 on NIH RePORTER |
What this research studies
This research investigates the impact of a Medicare policy change that expanded access to calcimimetics, medications used to treat secondary hyperparathyroidism in dialysis patients. By analyzing data from the United States Renal Data System, the study will compare prescribing patterns of these medications before and after the policy change. The goal is to understand how this change has influenced patient outcomes, including morbidity and mortality rates among those receiving dialysis. This research aims to provide insights into the effectiveness of policy interventions in improving treatment access for patients with end-stage kidney disease.
Who could benefit from this research
Good fit: Ideal candidates for this research are dialysis patients with end-stage kidney disease who have secondary hyperparathyroidism.
Not a fit: Patients who are not on dialysis or do not have secondary hyperparathyroidism may not benefit from this research.
Why it matters
Potential benefit: If successful, this research could lead to improved treatment access and outcomes for dialysis patients suffering from secondary hyperparathyroidism.
How similar studies have performed: Previous studies have shown that policy changes can significantly impact medication access and patient outcomes, suggesting that this approach has potential for success.
Where this research is happening
Stanford, United States
- Stanford University — Stanford, United States (Active)
Researchers
- Principal investigator: Caldwell, Jillian Scott — Stanford University
- Study coordinator: Caldwell, Jillian Scott
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page below.